Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use YESINTEK safely and effectively. See full prescribing information for YESINTEK. YESINTEK® (ustekinumab-kfce) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2024 YESINTEK ® (ustekinumab-kfce) is biosimilar* to STELARA® (ustekinumab).
Medication labelWhy this: Advisory · dailymed-prescription
YESINTEK is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. YESINTEK is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. YESINTEK is indicated for the treatment of adult patients with moderately to severely active Crohn's disease. YESINTEK is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
- generic_name
- ustekinumab
- product_names
- ustekinumab
- ndc
- 83257-024, 83257-026, 83257-025, 83257-023, 83257-024-11, 83257-025-41, 83257-026-11, 83257-023-41
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en